Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Children and Young Adults with Relapsed Ewing’s Sarcoma: A Systematic Review
Sarcoma · 03.06.2018 · 2018 · 1-12
DOI: 10.1155/2018/2640674 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Sarcoma, erschienen am 03.06.2018. Verfasst von Pavan Tenneti und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Arizona, Tucson, AZ 85721, USA. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health.
Themen: Onkologische Pflege, Kinderkrankenpflege
Abstract (Originalsprache)
Background
Relapsed Ewing’s sarcoma (RES) is an aggressive malignancy with poor survival. Although high-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) given after conventional chemotherapy (CC) has shown survival benefits, it is not generally used in the United States for RES. We performed a systemic review to evaluate the benefits of HDCT for RES.
Methods
Literature search involved Medline, Embase, and Cochrane database. We included studies with RES patients treated with HDCT/ASCT.
Results
Twenty-four studies with total of 345 reported RES patients that got HDCT were included in final analysis. Seventeen studies had patients with multiple malignancies including RES, while seven had only RES patients. At 2 and 3–5 years, event-free survival (EFS) in studies with only RES patients ranged 42–47% and 20–61% and overall survival (OS) ranged 50–66% and 33–77%, respectively. In studies with combined patients that reported outcomes of RES separately, the EFS at 1–3 and 4 years was 36–66% and 17–50%, respectively. The OS at 1-2 and 3-4 years was 40–60% and 50–70%.
Conclusions
Most studies using HDCT/ASCT as consolidation regimen showed improved survival benefits compared to CC. Randomized controlled studies are needed to determine true clinical benefits of HDCT followed by ASCT in patients with RES.
Autor:innen und Institutionen
- Department of Medicine, University of Arizona, Tucson, AZ 85721, USA.
- Department of Biostatics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ 85721, USA.
- Division of Hematology and Oncology, Department of Medicine, University of Arizona, Tucson, AZ 85721, USA.
- Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
ORCID-Profile: Pavan Tenneti, Seongseok Yun, Faiz Anwer
Förderung
- NCI NIH HHS
- National Institutes of Health
Zitieren
APA
Tenneti, P., Zahid, U., Iftikhar, A., Yun, S., Sohail, A., Warraich, Z., & Anwer, F. (2018). Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Children and Young Adults with Relapsed Ewing’s Sarcoma: A Systematic Review. Sarcoma, 2018, 1-12. https://doi.org/10.1155/2018/2640674
Vancouver
Tenneti P, Zahid U, Iftikhar A, Yun S, Sohail A, Warraich Z, et al. Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Children and Young Adults with Relapsed Ewing’s Sarcoma: A Systematic Review. Sarcoma. 2018;2018:1-12. doi:10.1155/2018/2640674
BibTeX
@article{Tenneti2018,
author = {Tenneti, Pavan and Zahid, Umar and Iftikhar, Ahmad and Yun, Seongseok and Sohail, Atif and Warraich, Zabih and Anwer, Faiz},
title = {Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Children and Young Adults with Relapsed Ewing’s Sarcoma: A Systematic Review},
journal = {Sarcoma},
year = {2018},
volume = {2018},
pages = {1--12},
doi = {10.1155/2018/2640674}
}
EUVIMED